An NHS spinout will be spotlighting its world-leading innovation in stroke treatment after being selected to showcase the breakthrough technology during a prestigious UK trade mission to India.
Biopharmaceutical company Aurum Biosciences will be furthering its global growth ambitions when it joins a Department for Business and Trade (DBT) visit from 16-19 February, encouraging fresh international connections through events, round table meetings, and pitching opportunities.
One focus of the trip will be the chance to engage global pharma companies and potential investors at the BioAsia 2026 Summit in Hyderabad, considered to be “Asia's foremost life sciences and healthcare event”.
Aurum’s patented ABL-101 platform technology has the potential to dramatically change that for the overwhelming 90% of patients currently missing out during emergencies through its promise to help treat the stroke-related oxygen deprivation which can quickly cause brain damage.
During Aurum’s visit to India – taking in Mumbai, Hyderabad, and Ahmedabad – the company aims to connect with partners who can help scale the company’s operations and further advance ABL-101.
ABL-101, which is being manufactured in India, has undergone significant pre-clinical development and has completed early phase 1 and 2a human studies. Phase 2 trials in stroke and inflammation imaging are planned this year, underlining its huge promise.
